RT journal article
T1 Secukinumab: Drug Survival in Clinical Practice Settings
A1 Ruiz-Villaverde, Ricardo
A1 Rodriguez Fernández-Freire, L.
A1 Galán-Gutiérrez, Manuel
A1 Armario Hita, José Carlos
A1 Martínez-Pilar, L.
A2 Medicina
K1 Secukinumab
K1 Drug survival
K1 Psoriasis
AB Secukinumab, an immunoglobulin G1/  monoclonal antibody that selectively targetsinterleukin 17a, is used to treat moderate to severe plaque psoriasis in adults who are eligiblefor systemic treatment. Indirect comparisons of the efficacy of secukinumab, ustekinumab,and anti-tumor necrosis factor agents have found lower drug survival rates for patients onsecukinumab, in spite of that biologic’s rapid onset of action and efficacy as demonstratedby the large number of patients reaching a Psoriasis Area and Severity Index of 90 or 100.We present data from a retrospective study of 171 patients treated with doses of 300 mg or150 mg of secukinumab every 4 weeks in 5 hospitals in the Spanish autonomous community ofAndalusia. Eighty-seven percent continued on treatment at 132 weeks, contrasting with reportsfrom previously published case series
PB ELSEVIER
SN 1578-2190
YR 2021
FD 2021
LK http://hdl.handle.net/10498/26335
UL http://hdl.handle.net/10498/26335
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 13-nov-2026